ERBB2 and breast cancer: The triple-negative phenotype, defined as the lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER-2) expression, represents approximately 15–20 % of breast cancer cases and has a worse clinical outcome and prognosis than other breast cancer subtypes [2–6].